01 3Movantik
02 4Movantik/Moventig
03 7Moventig
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 22
2019 Revenue in Millions : 19
Growth (%) : 15
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 24
2020 Revenue in Millions : 22
Growth (%) : 22
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 23
2021 Revenue in Millions : 24
Growth (%) : -1
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 12
2022 Revenue in Millions : 23
Growth (%) : -42
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 29
Growth (%) : New Launch
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 122
2016 Revenue in Millions : 91
Growth (%) : 34
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 109
2017 Revenue in Millions : 122
Growth (%) : -11%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 91
2015 Revenue in Millions : 29
Growth (%) : 214
Main Therapeutic Indication : Opioid-induced Constipation
Currency : USD
2017 Revenue in Millions : 34
2016 Revenue in Millions : 45
Growth (%) : -25
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 38
2017 Revenue in Millions : 31
Growth (%) : 20%
LOOKING FOR A SUPPLIER?